120 results on '"Targan S"'
Search Results
2. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
3. DOP29 Elevation of a novel blood-based gene signature in a severe Crohn’s disease (CD) subtype preceding surgery defines and predicts a post-surgical decrease in pro-inflammatory pathway activation
4. Antibodies to proinflammatory cytokines
5. New IBD markers: definition of disease heterogeneity
6. On the pathogenesis trail: what marker B cell clones tell us about IBD
7. Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI
8. Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFI
9. P343 Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study
10. OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
11. P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI
12. P317 Characterisation of patients with delayed response to ustekinumab for Crohn’s disease
13. DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
14. DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
15. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
16. A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY
17. A147 RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN’S STUDIES
18. P394 Preoperative serum vedolizumab levels do not predict postoperative outcomes in inflammatory bowel disease (IBD)
19. LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 2 YEARS
20. OC-043 Long term efficacy and safety of ustekinumab for crohn’s disease: results from im-uniti long-term extension through 2 years
21. OP010 Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years
22. P549 Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn’s disease
23. OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1
24. FRI0406 Prevalence and Significance of Radiographic Sacroiliitis in A Large Inflammatory Bowel Disease Population
25. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2: Abstract OC-007 Table 1
26. Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor
27. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables
28. Long-term outcomes of thalidomide in refractory Crohn's disease
29. Cytotoxic Lymphocytes in Human Intestinal Mucosa
30. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis
31. OP0241 Anti-Flagellin Antibodies in Ankylosing Spondylitis (AS) Implicate Subclinical Bowel Inflammation and Differentiate as from Mechanical Back Pain Patients
32. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism
33. P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease
34. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs disease
35. A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to Il-12/23p40, in Patients with Moderately to Severely Active Crohnʼs Disease: Results through Week 36 from the CERTIFI Trial: 2011 ACG Presidential Poster
36. Variants in ZNF365 isoform D are associated with Crohn's disease
37. Does Upper Endoscopy Impact the Diagnosis or Management of Adults with Colitis?
38. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine
39. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
40. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma
41. Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF- B activation
42. The CD8+ Leu-7+ subset of T cells in Crohn's disease: distinction between cytotoxic and covert suppressor functions
43. Natalizumab induces and maintains continuous response and remission in patients with active Crohnʼs disease despite prior anti-tumor necrosis factor-alpha treatment
44. Natalizumab is effective without the concomitant use of immunosuppressants or corticosteroids for the induction and maintenance of response and remission in patients with Crohnʼs disease
45. Candidate gene approach identifies CNR2 gene as associated with Crohnʼs disease
46. Candidate gene approach identifies CNR2 gene as associated with Crohnʼs disease: assigned haplotypes, protein expression, and functional data as defined by novel use of lymphoblastoid cell lines
47. Natalizumab induces and maintains continuous response and remission in patients with active Crohnʼs disease despite prior anti-tumor necrosis factor-alpha treatment
48. Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohnʼs Disease Who Failed Prior Anti-TNFα Therapy
49. Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteriods for the Induction of Sustained Response and Remission in Patients with Crohnʼs Disease
50. Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.